<DOC>
	<DOCNO>NCT02968927</DOCNO>
	<brief_summary>To examine safety preliminary efficacy multiple adjunctive host direct TB therapy ( TB HDT ) , assess potential shorten TB treatment and/or prevent permanent lung damage .</brief_summary>
	<brief_title>TB Host Directed Therapy</brief_title>
	<detailed_description>OBJECTIVES : To determine safety preliminary efficacy 4 TB HDT candidate : 1 . Safety ( treatment emergent serious adverse event SUSARs ) 2 . Microbiologic effect sputum ( culture conversion , change MGIT TTP ) blood ( WBA ) 3 . PET/CT image 4 . Serum marker inflammation 5 . Effects Mtb-specific general immune function 6 . Pulmonary effect ( spirometry , 6MWT , O2 saturation , St. George Respiratory Symptom Questionnaire ) In case , TB HDT effect determine comparison patient treated standard TB therapy alone regard common set primary secondary endpoint . PRIMARY ENDPOINTS 1 . For auranofin , everolimus , vitamin D : proportion patient experience suspect unexpected serious adverse reaction ( SUSARs ) . 2 . For CC-11050 : proportion patient experience treatment emergent serious adverse event ( SAEs ) .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<mesh_term>Auranofin</mesh_term>
	<criteria>1 . Willing able provide sign write consent witness oral consent case illiteracy , prior undertaking trialrelated procedure . 2 . Aged 18 65 year , male , female , either reproductive potential ( postmenopause , statuspost surgical sterilization ) intrauterine contraceptive device place . 3 . Body weight ( light clothing without shoe ) 40 90 kg . 4 . First episode pulmonary tuberculosis diagnose positive sputum AFB smear subsequent culture confirmation OR positive Xpert TB/RIF Ct &lt; 20 [ 4 ] . 5 . RIF susceptibility diagnose Xpert TB/RIF OR Hain test 6 . Chest radiograph meeting criterion moderate far advanced pulmonary tuberculosis [ 5 ] 7 . HIV1 seronegative 8 . HBsAg negative 1 . Any condition participation trial , judge investigator , could compromise wellbeing subject prevent , limit confound protocol specify assessment 2 . Current imminent treatment malaria . 3 . Is critically ill , judgment investigator diagnosis likely result death trial followup period . 4 . TB meningitis form severe tuberculosis high risk poor outcome judge investigator . 5 . History allergy hypersensitivity trial therapy relate substance , include know allergy suspect hypersensitivity rifampin rifabutin . 6 . Having participated clinical trial investigational agent within 8 week prior trial start currently enrol investigational trial . 7 . Subjects follow screening : 1 . Cardiac arrhythmia require medication ; 2 . Prolongation QT/QTc interval QTcF ( Fridericia correction ) &gt; 450 m ; 3 . History additional risk factor Torsade de Pointes , ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) ; 4 . Any clinically significant ECG abnormality , opinion investigator . 5 . Patients require concomitant medication prolong QT interval . 8 . Random blood glucose &gt; 140 mg/dL , history unstable Diabetes Mellitus require hospitalization hyper hypoglycaemia within past year prior start screening . 9 . Use systemic corticosteroid within past 28 day . 10 . Subjects follow abnormal laboratory value : 1. creatinine &gt; 2 mg/dL 2. haemoglobin &lt; 8 g/dL 3. platelet &lt; 100x109 cells/L 4. serum potassium &lt; 3.5 5. aspartate aminotransferase ( AST ) â‰¥2.0 x ULN 6. alkaline phosphatase ( AP ) &gt; 5.0 x ULN 7. total bilirubin &gt; 1.5 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>